Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

The MDM2 inhibitor Nutlin-3 attenuates streptozotocin-induced diabetes mellitus and increases serum level of IL-12p40.

Secchiero P, Toffoli B, Melloni E, Agnoletto C, Monasta L, Zauli G.

Acta Diabetol. 2013 Dec;50(6):899-906. doi: 10.1007/s00592-013-0476-8. Epub 2013 Apr 25.

PMID:
23615706
2.

Inhibition of MDM2 attenuates neointimal hyperplasia via suppression of vascular proliferation and inflammation.

Hashimoto T, Ichiki T, Ikeda J, Narabayashi E, Matsuura H, Miyazaki R, Inanaga K, Takeda K, Sunagawa K.

Cardiovasc Res. 2011 Sep 1;91(4):711-9. doi: 10.1093/cvr/cvr108. Epub 2011 Apr 14.

PMID:
21498419
3.

MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway.

Zauli G, Rimondi E, Corallini F, Fadda R, Capitani S, Secchiero P.

J Bone Miner Res. 2007 Oct;22(10):1621-30.

4.

Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.

Mouraret N, Marcos E, Abid S, Gary-Bobo G, Saker M, Houssaini A, Dubois-Rande JL, Boyer L, Boczkowski J, Derumeaux G, Amsellem V, Adnot S.

Circulation. 2013 Apr 23;127(16):1664-76. doi: 10.1161/CIRCULATIONAHA.113.002434. Epub 2013 Mar 19.

5.

E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.

Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.

Oncogene. 2008 Sep 11;27(40):5303-14. doi: 10.1038/onc.2008.164. Epub 2008 Jun 2.

PMID:
18521084
6.

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.

PMID:
19903807
7.

Potent in vitro and in vivo antitumor effects of MDM2 inhibitor nutlin-3 in gastric cancer cells.

Endo S, Yamato K, Hirai S, Moriwaki T, Fukuda K, Suzuki H, Abei M, Nakagawa I, Hyodo I.

Cancer Sci. 2011 Mar;102(3):605-13. doi: 10.1111/j.1349-7006.2010.01821.x. Epub 2011 Jan 12.

8.

Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.

9.

Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.

Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.

PMID:
21484514
10.

Antiangiogenic activity of the MDM2 antagonist nutlin-3.

Secchiero P, Corallini F, Gonelli A, Dell'Eva R, Vitale M, Capitani S, Albini A, Zauli G.

Circ Res. 2007 Jan 5;100(1):61-9. Epub 2006 Nov 30.

11.

Interleukin-17A deficiency ameliorates streptozotocin-induced diabetes.

Tong Z, Liu W, Yan H, Dong C.

Immunology. 2015 Oct;146(2):339-46. doi: 10.1111/imm.12512. Epub 2015 Sep 9.

12.

Nutlin-3 downregulates the expression of the oncogene TCL1 in primary B chronic lymphocytic leukemic cells.

Voltan R, di Iasio MG, Bosco R, Valeri N, Pekarski Y, Tiribelli M, Secchiero P, Zauli G.

Clin Cancer Res. 2011 Sep 1;17(17):5649-55. doi: 10.1158/1078-0432.CCR-11-1064. Epub 2011 Jul 13.

13.

Intraperitoneal co-administration of thymosin alpha-1 ameliorates streptozotocin-induced pancreatic lesions and diabetes in C57BL/6 mice.

Qiu L, Zhang C, Zhang J, Liang J, Liu J, Ji C, Yang JY.

Int J Mol Med. 2009 May;23(5):597-602.

PMID:
19360317
14.

MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity.

Saha MN, Jiang H, Jayakar J, Reece D, Branch DR, Chang H.

Cancer Biol Ther. 2010 Jun 1;9(11):936-44. Epub 2010 Jun 27.

PMID:
20418664
15.

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J Jr.

Cancer Res. 2009 Jan 15;69(2):416-21. doi: 10.1158/0008-5472.CAN-08-1856.

16.

Nutlin-3, a small-molecule MDM2 inhibitor, sensitizes Caki cells to TRAIL-induced apoptosis through p53-mediated PUMA upregulation and ROS-mediated DR5 upregulation.

Park EJ, Choi KS, Yoo YH, Kwon TK.

Anticancer Drugs. 2013 Mar;24(3):260-9. doi: 10.1097/CAD.0b013e32835c0311.

PMID:
23187459
17.

A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis.

Cho JM, Jang HW, Cheon H, Jeong YT, Kim DH, Lim YM, Choi SH, Yang EK, Shin CY, Son MH, Kim SH, Kim HJ, Lee MS.

Diabetes Res Clin Pract. 2011 Jan;91(1):72-9. doi: 10.1016/j.diabres.2010.10.012. Epub 2010 Nov 18.

PMID:
21093089
18.

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.

Wang B, Fang L, Zhao H, Xiang T, Wang D.

Acta Biochim Biophys Sin (Shanghai). 2012 Aug;44(8):685-91. doi: 10.1093/abbs/gms053.

PMID:
22843172
19.

Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.

Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M, Andreeff M, Rassidakis GZ.

Clin Cancer Res. 2007 Jun 1;13(11):3380-7.

20.

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

Aziz MH, Shen H, Maki CG.

Oncogene. 2011 Nov 17;30(46):4678-86. doi: 10.1038/onc.2011.185. Epub 2011 Jun 6.

Supplemental Content

Support Center